{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003304","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.013780+00:00","generated_at":"2026-05-24T11:29:46.004316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Capricor Therapeutics reports Q4 net loss $7.1M, BLA for deramiocel accepted with PDUFA Aug 31, 2025","bullets":["FDA accepted BLA for deramiocel to treat DMD cardiomyopathy; Priority Review, PDUFA date August 31, 2025.","HOPE-2 OLE data showed 52% slowing of disease progression over 3 years vs external comparator (p=0.019).","Cash balance $151.5M at Dec 31, 2024; received $10M milestone from Nippon Shinyaku in Jan 2025; cash runway into 2027.","Q4 2024 revenue $11.1M (vs $12.1M Q4 2023); net loss $7.1M ($0.16/share) vs $0.8M loss ($0.02/share).","Full year 2024 net loss $40.5M ($1.15/share) vs $22.3M ($0.83/share) in 2023; operating expenses $64.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003304","json":"https://secwatch.observer/filing/0001558370-25-003304.json","markdown":"https://secwatch.observer/filing/0001558370-25-003304.md","text":"https://secwatch.observer/filing/0001558370-25-003304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/0001558370-25-003304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:29:46.004316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}